MiNK Therapeutics Reports Third Quarter 2023 Results
- MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.
- AgenT-797 demonstrates potential beyond cancer, with improved survival in severe respiratory distress. MiNK plans for expansion in autoimmune and inflammatory diseases.
- Conference Call on
Thursday, November 9, 2023, at 8:30 a.m. ET.
"This quarter we made important advancements across our iNKT cell platform, including new data that demonstrated the long-term persistence and clinical benefits of iNKTs in heavily pretreated solid tumor cancer patients,” said Dr.
AgenT-797 has shown promising results in patients with late-stage metastatic cancer, including NSCLC, testicular, appendiceal, and gastric cancers, refractory to traditional therapies. More than 30% of these patients experienced disease stabilization or biomarker responses, and a patient with gastric cancer achieved a durable clinical response. This is especially significant, considering agenT-797’s administration does not require HLA matching or toxic pre-conditioning, setting a new standard in the field of cell therapy.
A randomized phase 2 clinical trial of agenT-797 +/- standard of care chemotherapy +/- Agenus’ botensilimab/balstilimab in patients with 2L gastric cancer is on track to launch this year. The trial will be externally funded and led by Dr.
We ended the third quarter with a cash balance of
Net loss for the nine-months ended
|Summary Consolidated Financial Information|
|Condensed Consolidated Balance Sheet Data|
|Cash and cash equivalents||$||6,399||$||19,636|
|Other Financial Information|
|Three months ended
||Nine months ended
|Cash used in operations||$||4,209||$||5,615||$||12,727||$||14,436|
|Non-cash operating expenses (income)||$||993||$||(1,989||)||2,643||$||(348||)|
|Condensed Consolidated Statements of Operations Data|
|(in thousands, except per share data)|
|Three months ended
||Nine months ended
|Research and development||3,427||6,150||12,179||17,303|
|General and administrative||1,796||1,838||5,242||5,757|
|Other income, net||(107||)||(1,656||)||(422||)||(2,838||)|
|Per common share data, basic and diluted:|
|Weighted average number of common shares outstanding, basic and diluted||34,498||33,757||34,293||33,628|
Conference ID: 8819822
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/uns7ovrj/.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797 alone and in combination with anti-PD-1, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K, Form 10-Q and the S-1 Registration Statement filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Source: MiNK Therapeutics